Level	Gene	Alterations	Cancer Types	Drugs (for therapeutic implications only)
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Imatinib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Asciminib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Bosutinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Dasatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Imatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Nilotinib
1	ABL1	T315I	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib
1	ABL1	T315I	Chronic Myelogenous Leukemia	Asciminib
1	ABL1	T315I	Chronic Myelogenous Leukemia	Ponatinib
1	AKT1	E17K	Breast Cancer	Capivasertib + Fulvestrant
1	ALK	Fusions	Anaplastic Large-Cell Lymphoma ALK Positive	Crizotinib
1	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Crizotinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Alectinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Brigatinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Ceritinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Ensartinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Lorlatinib
1	ATM	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	ATM	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	ATR	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	BARD1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRAF	Fusions	Low-Grade Glioma, NOS	Tovorafenib
1	BRAF	V600	Erdheim-Chester Disease	Vemurafenib
1	BRAF	V600	Low-Grade Glioma, NOS	Tovorafenib
1	BRAF	V600	Melanoma	Vemurafenib + Atezolizumab + Cobimetinib
1	BRAF	V600E	All Solid Tumors (excluding Colorectal Cancer)	Dabrafenib + Trametinib
1	BRAF	V600E	Anaplastic Thyroid Cancer	Dabrafenib + Trametinib
1	BRAF	V600E	Colorectal Cancer	Encorafenib + Cetuximab
1	BRAF	V600E	Colorectal Cancer	Encorafenib + Cetuximab + FOLFOX Regimen
1	BRAF	V600E	Hepatobiliary Cancer, Biliary Tract	Dabrafenib + Trametinib
1	BRAF	V600E	Low-Grade Glioma, NOS	Dabrafenib + Trametinib
1	BRAF	V600E	Melanoma	Dabrafenib
1	BRAF	V600E	Melanoma	Vemurafenib
1	BRAF	V600E	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib
1	BRAF	V600E	Non-Small Cell Lung Cancer	Encorafenib + Binimetinib
1	BRAF	V600E, V600K	Melanoma	Dabrafenib + Trametinib
1	BRAF	V600E, V600K	Melanoma	Encorafenib + Binimetinib
1	BRAF	V600E, V600K	Melanoma	Trametinib
1	BRAF	V600E, V600K	Melanoma	Vemurafenib + Cobimetinib
1	BRCA1	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Niraparib
1	BRCA1	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Olaparib
1	BRCA1	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Olaparib + Bevacizumab
1	BRCA1	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Rucaparib
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Niraparib + Abiraterone Acetate + Prednisone
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib + Abiraterone + Prednisone
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Rucaparib
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	BRCA2	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Niraparib
1	BRCA2	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Olaparib
1	BRCA2	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Olaparib + Bevacizumab
1	BRCA2	Oncogenic Mutations	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Rucaparib
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Niraparib + Abiraterone Acetate + Prednisone
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib + Abiraterone + Prednisone
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Rucaparib
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	BRIP1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CDK12	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CDK12	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	CHEK1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CHEK2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CHEK2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Amivantamab + Chemotherapy
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Amivantamab + Lazertinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Dacomitinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Erlotinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Erlotinib + Ramucirumab
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Gefitinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Osimertinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Osimertinib + Chemotherapy
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Amivantamab
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Amivantamab + Chemotherapy
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Sunvozertinib
1	EGFR	G719	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	L861Q	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	Oncogenic Mutations	Non-Small Cell Lung Cancer	Datopotamab Deruxtecan
1	EGFR	S768I	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	T790M	Non-Small Cell Lung Cancer	Osimertinib
1	ERBB2	Amplification	Breast Cancer	Ado-Trastuzumab Emtansine
1	ERBB2	Amplification	Breast Cancer	Lapatinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Lapatinib + Letrozole
1	ERBB2	Amplification	Breast Cancer	Margetuximab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Neratinib
1	ERBB2	Amplification	Breast Cancer	Neratinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Trastuzumab
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Pertuzumab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Tucatinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Trastuzumab Deruxtecan
1	ERBB2	Amplification	Colorectal Cancer	Tucatinib + Trastuzumab
1	ERBB2	Amplification	Esophagogastric Cancer	Pembrolizumab + Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Esophagogastric Cancer	Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Esophagogastric Cancer	Trastuzumab Deruxtecan
1	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Trastuzumab Deruxtecan
1	ESR1	D538, E380, L469V, L536, S463P, Y537	Breast Cancer	Elacestrant
1	EZH2	A682G, A692V, Y646C, Y646F, Y646H, Y646N, Y646S	Follicular Lymphoma	Tazemetostat
1	FANCA	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	FANCL	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	FGFR1	Fusions	Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2	Pemigatinib
1	FGFR2	Fusions	Cholangiocarcinoma	Futibatinib
1	FGFR2	Fusions	Cholangiocarcinoma	Pemigatinib
1	FGFR3	FGFR3-BAIAP2L1 Fusion, FGFR3-TACC3 Fusion	Bladder Cancer	Erdafitinib
1	FGFR3	G370C, R248C, S249C, Y373C	Bladder Cancer	Erdafitinib
1	FLT3	D835, I836, Internal tandem duplication	Acute Myeloid Leukemia	Gilteritinib
1	FLT3	D835, I836, Internal tandem duplication	Acute Myeloid Leukemia	Midostaurin + High Dose Chemotherapy
1	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Quizartinib
1	IDH1	R132C, R132G, R132H, R132L, R132S	Acute Myeloid Leukemia	Ivosidenib
1	IDH1	R132C, R132G, R132H, R132L, R132S	Acute Myeloid Leukemia	Olutasidenib
1	IDH1	R132C, R132G, R132H, R132L, R132S	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib
1	IDH1	R132C, R132G, R132H, R132L, R132S	Myelodysplastic Syndromes	Ivosidenib
1	IDH1	R132C, R132G, R132H, R132L, R132S	Oligodendroglioma, Astrocytoma	Vorasidenib
1	IDH2	R140G, R140L, R140Q, R140W, R172G, R172K, R172M, R172S, R172W	Acute Myeloid Leukemia	Enasidenib
1	IDH2	R172G, R172K, R172M, R172S, R172W	Oligodendroglioma, Astrocytoma	Vorasidenib
1	KIT	D816	Mastocytosis	Avapritinib
1	KIT	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Sunitinib
1	KMT2A	Fusions	Acute Leukemias of Ambiguous Lineage	Revumenib
1	KMT2A	Fusions	Acute Myeloid Leukemia	Revumenib
1	KMT2A	Fusions	B-Lymphoblastic Leukemia/Lymphoma	Revumenib
1	KRAS	G12C	Colorectal Cancer	Adagrasib + Cetuximab
1	KRAS	G12C	Colorectal Cancer	Sotorasib + Panitumumab
1	KRAS	G12C	Non-Small Cell Lung Cancer	Adagrasib
1	KRAS	G12C	Non-Small Cell Lung Cancer	Sotorasib
1	KRAS	Oncogenic Mutations	Low-Grade Serous Ovarian Cancer	Avutometinib + Defactinib
1	KRAS	Wildtype	Colorectal Cancer	Cetuximab
1	KRAS	Wildtype	Colorectal Cancer	Cetuximab + Chemotherapy
1	KRAS	Wildtype	Colorectal Cancer	Panitumumab
1	KRAS	Wildtype	Colorectal Cancer	Panitumumab + Chemotherapy
1	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Capmatinib
1	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Tepotinib
1	MLH1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	MRE11	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	NBN	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	NF1	Oncogenic Mutations	Neurofibroma	Mirdametinib
1	NF1	Oncogenic Mutations	Neurofibroma	Selumetinib
1	NRAS	Wildtype	Colorectal Cancer	Panitumumab
1	NRAS	Wildtype	Colorectal Cancer	Panitumumab + Chemotherapy
1	NRG1	Fusions	Non-Small Cell Lung Cancer	Zenocutuzumab
1	NRG1	Fusions	Pancreatic Adenocarcinoma	Zenocutuzumab
1	NTRK1	Fusions	All Solid Tumors	Entrectinib
1	NTRK1	Fusions	All Solid Tumors	Larotrectinib
1	NTRK1	Fusions	All Solid Tumors	Repotrectinib
1	NTRK2	Fusions	All Solid Tumors	Entrectinib
1	NTRK2	Fusions	All Solid Tumors	Larotrectinib
1	NTRK2	Fusions	All Solid Tumors	Repotrectinib
1	NTRK3	Fusions	All Solid Tumors	Entrectinib
1	NTRK3	Fusions	All Solid Tumors	Larotrectinib
1	NTRK3	Fusions	All Solid Tumors	Repotrectinib
1	Other Biomarkers	Microsatellite Instability-High	All Solid Tumors	Pembrolizumab
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Ipilimumab + Nivolumab
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Nivolumab
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Pembrolizumab
1	Other Biomarkers	Microsatellite Instability-High	Endometrial Cancer	Dostarlimab + Carboplatin + Paclitaxel
1	Other Biomarkers	Microsatellite Instability-High	Endometrial Cancer	Pembrolizumab
1	Other Biomarkers	Tumor Mutational Burden-High	All Solid Tumors	Pembrolizumab
1	PALB2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	PALB2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	PDGFB	COL1A1-PDGFB Fusion	Dermatofibrosarcoma Protuberans	Imatinib
1	PDGFRA	Exon 18 in-frame deletions, Exon 18 in-frame insertions, Exon 18 missense mutations	Gastrointestinal Stromal Tumor	Avapritinib
1	PDGFRA	FIP1L1-PDGFRA Fusion	Chronic Eosinophilic Leukemia, NOS	Imatinib
1	PDGFRA	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib
1	PDGFRB	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib
1	PIK3CA	C420R, E542K, E545A, E545D, E545G, E545K, H1047L, H1047R, H1047Y, Q546E, Q546R	Breast Cancer	Alpelisib + Fulvestrant
1	PIK3CA	C420R, E542K, E545A, E545D, E545G, E545K, H1047L, H1047R, H1047Y, Q546E, Q546R	Breast Cancer	Capivasertib + Fulvestrant
1	PIK3CA	E545Q, G1049R, M1043I, M1043V, N345K, Q546K, Q546P, R88Q	Breast Cancer	Capivasertib + Fulvestrant
1	PIK3CA	Oncogenic Mutations	Breast Cancer	Inavolisib + Palbociclib + Fulvestrant
1	PTEN	Oncogenic Mutations	Breast Cancer	Capivasertib + Fulvestrant
1	RAD51B	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD51C	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD51C	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Talazoparib + Enzalutamide
1	RAD51D	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD54L	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RARA	PML-RARA Fusion	APL with PML-RARA	Arsenic Trioxide
1	RARA	PML-RARA Fusion	APL with PML-RARA	Tretinoin
1	RARA	PML-RARA Fusion	APL with PML-RARA	Tretinoin + Arsenic Trioxide
1	RET	Fusions	All Solid Tumors	Selpercatinib
1	RET	Fusions	Non-Small Cell Lung Cancer	Pralsetinib
1	RET	Fusions	Non-Small Cell Lung Cancer	Selpercatinib
1	RET	Fusions	Thyroid Cancer	Pralsetinib
1	RET	Fusions	Thyroid Cancer	Selpercatinib
1	RET	Oncogenic Mutations	Medullary Thyroid Cancer	Selpercatinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Entrectinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Repotrectinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Taletrectinib
1	SMARCB1	Deletion	Epithelioid Sarcoma	Tazemetostat
1	TSC1	Oncogenic Mutations	Encapsulated Glioma	Everolimus
1	TSC2	Oncogenic Mutations	Encapsulated Glioma	Everolimus